At what enterprise value was PHARMATHEN acquired in 2015?

During the acquisition of PHARMATHEN by BC PARTNERS in 2015, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

When was PHARMATHEN acquired by BC PARTNERS?

PHARMATHEN was acquired by BC PARTNERS in 2015.

What was the revenue of PHARMATHEN at the time of the deal?

The revenue of PHARMATHEN at the time of the deal is estimated to be in the range of 100M - 200M EUR.

How is the data for the PHARMATHEN acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PHARMATHEN deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.bcpartners.com/news/bc-partners-sells-pharmathen-to-partners-group/

← DATABASE

Home Database Healthcare & PharmaPHARMATHEN

06/2015

PHARMATHEN acquired by BC PARTNERS

GREECE Life Sciences / Pharma & Biotech / CDMO EV 300M - 700M EUR

Context

BC Partners reached an agreement to acquire a majority stake in Pharmathen, partnering with the company's founders who retain a minority shareholding and remain actively involved in the business. The investment thesis centres on leveraging Pharmathen's strong existing platform to pursue selective bolt-on acquisitions, accelerate new product development, and drive international expansion in the growing complex generics pharmaceutical sector. BC Partners intends to support Pharmathen in its ambition to transition from an established European champion into a global pharmaceutical player.

PHARMATHEN, which reported an EBITDA margin of in 2014, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Pharmathen is a leading European pharmaceutical and drug delivery technology company founded in 1969, specialising in the development and manufacturing of complex "sustained release" drug delivery technologies. The company is the global leader in complex long-acting injectables (LAI) and has established a long-acting therapeutic technologies (LATT) platform, positioning it at the forefront of one of the most technically demanding and high-barrier segments of the pharmaceutical industry. Pharmathen operates a highly differentiated business model combining best-in-class R&D capabilities with FDA-approved manufacturing facilities, serving a blue-chip customer base across nearly 100 countries worldwide.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2014

2013

Other operations with PHARMATHEN

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2021	PARTNERS GROUP	PHARMATHEN	GREECE	CDMO

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PHARMATHEN by BC PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: bc partners